{"id":868768,"date":"2025-07-11T07:38:18","date_gmt":"2025-07-11T11:38:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/"},"modified":"2025-07-11T07:38:18","modified_gmt":"2025-07-11T11:38:18","slug":"briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/","title":{"rendered":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>No treatment related discontinuations reported <\/em><br \/>\n          <\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, July  11, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI).<\/p>\n<p align=\"justify\">The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent chemotherapy data. BriaCell\u2019s median OS has improved from 11.4 months last <a href=\"https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=8470896771035848&amp;symbol=BCTX\" rel=\"nofollow\" target=\"_blank\">reported at ASCO in June 2025<\/a>.<sup>1<\/sup><\/li>\n<li style=\"text-align:justify\">Hormone receptor positive (HR+): median overall survival (OS) of 17.3 months vs. 14.4 months for Trodelvy and 11.2 months in single agent chemotherapy data.<\/li>\n<\/ul>\n<p align=\"justify\">\u201cWe are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients,\u201d stated Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cBriaCell\u2019s patients had failed a median of six prior therapies, underscoring the potential clinical impact of our novel immunotherapy. We look forward to validating these findings in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint.\u201d<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"6\">\n            <strong>Table 1: Analysis of survival data for BriaCell\u2019s Phase 2 study versus Trodelvy in MBC patient subsets<\/p>\n<p><\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Breast Cancer <br \/>Type<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Treatment<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Median<br \/> # of prior<br \/> lines of<br \/> therapy<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Median<br \/> Overall<br \/> Survival<br \/> (months)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Survival<br \/> rate at 6 <br \/>months (%)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Survival <br \/>rate at 12<br \/> months (%)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong><br \/>\n              <br \/>TNBC<\/strong>\u00a0<\/p>\n<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Bria-IMT plus CPI*<\/strong><br \/>\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>\u00a0<\/strong><br \/>\n            <strong>6<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>13.9<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>78<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>56<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <br \/> TNBC<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Trodelvy<sup>1<\/sup><br \/>(sacituzumab govitecan-hziy)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">3**<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">11.8<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">80***<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">49***<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Single agent chemotherapy<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">3**<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">6.9<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">56***<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">22***<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong><br \/>\n              <br \/>HR+<\/strong><br \/>\n            <strong>\u00a0<\/p>\n<p><\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Bria-IMT plus CPI*<\/strong><br \/>\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>6<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>17.3<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>90<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>61<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <br \/> HR+<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Trodelvy<sup>1<\/sup><br \/>(sacituzumab govitecan-hziy)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">4<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">14.4<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">83***<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">61<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Single agent chemotherapy<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">4<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">11.2<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">76***<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">47<\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\">* Patients treated with the Phase 3 formulation<br \/>** Prior chemotherapy-containing regimens<br \/>*** Derived from published Kaplan-Meier curves see<sup>1<\/sup><br \/>\u00a0 \u00a0 1.\u00a0\u00a0<a href=\"https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf<\/a><a href=\"https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf\" rel=\"nofollow\" target=\"_blank\"><\/p>\n<p><\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Abbreviations: <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>TNBC:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Triple-negative breast cancer (lacks the estrogen receptor, progesterone receptor, and lacks or has low levels of human epidermal growth factor receptor 2 (HER2))<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">As shown in table 1, median OS number with Bria-IMT is higher than that reported in the treatment arm of the ASCENT study (SG) for TNBC patients, and twice that reported in treatment of physician\u2019s choice arm.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>HR+<\/em><br \/>\n        <\/strong><br \/>\n        <em>: hormone receptor-positive<\/em>\n      <\/p>\n<p align=\"justify\">The Phase 2 Bria-IMT study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 received the same formulation currently being used in BriaCell\u2019s ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=82nAjBsgZ5sBHBfAOMAEArE4FBLz6lwVbO2zecESr5fozEy5m4Jmw1_vGdGtS7IEYs93BdePSTQvV_93cicdK7Q9-LcEtty7QoUVPMT8Oog2sbwIUbJFEhwmWw8OllpV\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>). No Bria-IMT related discontinuations have been reported to date.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7rDWronaYqBIAejJ3573AhEroX1NEozEn3Qnpk9PQB4Q4SQuSQL6Bvtc2UvqIFQ-F3e1K09WRqYwlKm7MShjkvgXvOvgwa_Fk0jDEm4KPN0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about BriaCell validating positive findings in its ongoing pivotal Phase 3 study with overall survival as its primary endpoint, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EKtB4yuFBsK5Q3eRojgVCfGvaoOuXttvgX1U68k2iwflfDfzuMXP7Vu5xZBtXGD7-LxH5HPIi-8aHbZ9h0XlL8wrw4DD2PNOp2YmtcmsdVo=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca<\/strong><\/a> and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EKtB4yuFBsK5Q3eRojgVCaz_xeN_y1FwIJnt6XD00K81sNcVLaz_E2PekM8ckaBHD2sF3nNoxC0DKmucmH3VvQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5-Hw7SPCmg-3Je3Z_Q0PxwvhMVTXfsf9RX4kaSySVEDwXmhbu1lh0omn7j9dHaL8SRGBCGxREGSWM3VAxiwFRAHd1RA6uz0EI_V9KbjsV_I=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X753-Pv-IpPvXQGSZ5vdHWP96Vzw8Y63vp4hG9YUIXTRfTPAQ9Pkakxcryg-vqbSgCG0iU10M5efDdWfrOD3kS88kDKPgYSyeCF3I8SUe6o=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <sup>1<\/sup><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7rDWronaYqBIAejJ3573Asl78lcSsG_yCSLOfJwGj2Mp7ylIhoji4bPgoSW8pcBPkRuxeW_pyKeZShsxLRPWVeYcmBIWrwWIRlHlTm2hhFbjXDdOIfiNvN01HCXgprFWKnDxjcRAlVv4tepikksWRbKXuVJdyaJLgRAkQHl5potUEeA5Iu7Dv1yIO5AQ9wf3fu_jVZei0XZzVGnhUVyEap1tRo0pbj0ggAMCJVZeOdZQS17-9YyzhvI7ZsqxLR8SMI3l84-GU0MUa2v5vm_tPQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmI5OTUxZTEtYTczMS00OWM4LTgxYmEtNjhkNzU4MDBhY2YzLTExMDIyMjktMjAyNS0wNy0xMS1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months) No treatment related discontinuations reported PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI). The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes: Triple negative breast &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868768","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months) No treatment related discontinuations reported PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI). The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes: Triple negative breast &hellip; Continue reading &quot;BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T11:38:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer\",\"datePublished\":\"2025-07-11T11:38:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/\"},\"wordCount\":827,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/\",\"name\":\"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\",\"datePublished\":\"2025-07-11T11:38:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk","og_description":"Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months) No treatment related discontinuations reported PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI). The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes: Triple negative breast &hellip; Continue reading \"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-11T11:38:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer","datePublished":"2025-07-11T11:38:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/"},"wordCount":827,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/","name":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=","datePublished":"2025-07-11T11:38:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5Mjg1OCM3MDQzMDY4IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell\u2019s Bria-IMT\u2122 Demonstrates Survival Advantage over Trodelvy\u00ae and Control Group in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868768"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}